Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas

Brain Pathology

Volumn 19, Issue 2, 2009, Pages 188-194

  Zawlik, Izabela ^a   Kita, Daisuke ^a   Vaccarella, Salvatore ^a   Mittelbronn, Michel ^b   Franceschi, Silvia ^a   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Glioblastoma; MDM2 amplification; MDM2 SNP 309; p14ARF alteration; TP53 codon 72 polymorphism; TP53 mutation

Indexed keywords

ARGININE; PROLINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CODON; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MDM2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE;

AGE FACTORS; BRAIN NEOPLASMS; FEMALE; GENES, P53; GENOTYPE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; SEX FACTORS;

EID: 61649116731     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2008.00170.x     Document Type: Article

References (59)

1. Barak Y, Gottlieb E, Juven Gershon T, Oren M (1994) Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 8 : 1739 1749.
2. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H (1997) Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56 : 180 185.
3. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 : 591 602.
4. Bond GL, Hu W, Levine AJ (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5 : 3 8.
5. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L et al (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43 : 531 533.
6. Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, Omata M (2006) MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 12 : 4867 4871.
7. Dumont P, Leu JI, Della PA, III., George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 : 357 365.
8. El Hallani S, Marie Y, Idbaih A, Rodero M, Boisselier B, Laigle-Donadey F et al (2007) No association of MDM2 SNP309 with risk of glioblastoma and prognosis. J Neurooncol 85 : 241 244.
9. INK4a methylation and p53 mutational status. Cancer Res 60 : 129 133.
10. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, Christiani DC (2000) The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9 : 1037 1042.
11. Galic V, Willner J, Wollan M, Garg R, Garcia R, Goff BA et al (2007) Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 46 : 239 247.
12. Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R (2007) MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 13 : 4123 4129.
13. Holtkamp N, Atallah I, Okuducu AF, Mucha J, Hartmann C, Mautner VF et al (2007) MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia 9 : 671 677.
14. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y et al (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65 : 9582 9587.
15. Hu Y, McDermott MP, Ahrendt SA (2005) The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 11 : 2502 2509.
16. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M et al (2003) Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10 : 307 311.
17. Khan S, Abdelrahim M, Samudio I, Safe S (2003) Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17beta-estradiol in breast cancer cells. Endocrinology 144 : 2325 2335.
18. Kinyamu HK, Archer TK (2003) Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol Cell Biol 23 : 5867 5881.
19. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK (2000) Glioblastoma. In : Pathology and Genetics of Tumours of the Nervous System. P Kleihues, WK Cavenee (eds), pp. 29 39. IARC Press : Lyon.
20. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A (2006) Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119 : 718 721.
21. Malmer B, Feychting M, Lonn S, Ahlbom A, Henriksson R (2005) p53 Genotypes and risk of glioma and meningioma. Cancer Epidemiol Biomarkers Prev 14 : 2220 2223.
22. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA et al (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25 : 47 54.
23. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME (2003) mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23 : 462 472.
24. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G et al (2006) Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98 : 285 288.
25. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 : 1237 1245.
26. Arf deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11 : 159 168.
27. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64 : 479 489.
28. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170 : 1445 1453.
29. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64 : 6892 6899.
30. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H (2006) MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 24 : 4434 4440.
31. Okumura N, Saji S, Eguchi H, Nakashima S, Saji S, Hayashi S (2002) Distinct promoter usage of mdm2 gene in human breast cancer. Oncol Rep 9 : 557 563.
32. Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F et al (1999) Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol 155 : 105 113.
33. Parhar P, Ezer R, Shao Y, Allen JC, Miller DC, Newcomb EW (2005) Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res 137 : 98 103.
34. Petz LN, Ziegler YS, Schultz JR, Kim H, Kemper JK, Nardulli AM (2004) Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites. J Steroid Biochem Mol Biol 88 : 113 122.
35. Phelps M, Darley M, Primrose JN, Blaydes JP (2003) p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res 63 : 2616 2623.
36. Picksley SM, Lane DP (1993) The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 15 : 689 690.
37. Qi JS, Yuan Y, Desai-Yajnik V, Samuels HH (1999) Regulation of the mdm2 oncogene by thyroid hormone receptor. Mol Cell Biol 19 : 864 872.
38. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP (1993) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53 : 2736 2739.
39. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP (1994) Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54 : 4299 4303.
40. Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R et al (2007) The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 15 : 110 114.
41. Sakamuro D, Sabbatini P, White E, Prendergast GC (1997) The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15 : 887 898.
42. Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A (2004) Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 6 : 529 535.
43. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 : 1011 1018.
44. Stoner M, Wormke M, Saville B, Samudio I, Qin C, Abdelrahim M, Safe S (2004) Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins. Oncogene 23 : 1052 1063.
45. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17 : 5001 5014.
46. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19 : 1092 1100.
47. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11 : 5098 5103.
48. Tsuiki H, Nishi T, Takeshima H, Yano S, Nakamura H, Makino K, Kuratsu J (2007) Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis. Neurol Med Chir (Tokyo) 47 : 203 208.
49. van Heemst D, Mooijaart SP, Beekman M, Schreuder J, de Craen AJ, Brandt BW et al (2005) Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 40 : 11 15.
50. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408 : 307 310.
51. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8 : 275 283.
52. Walker KK, Levine AJ (1996) Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 93 : 15335 15340.
53. Walsh CS, Miller CW, Karlan BY, Koeffler HP (2007) Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 104 : 660 664.
54. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK et al (2002) p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94 : 681 690.
55. Wu HC, Chang CH, Chen HY, Tsai FJ, Tsai JJ, Chen WC (2004) p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol Int 73 : 41 46.
56. Xing EP, Yang GY, Wang LD, Shi ST, Yang CS (1999) Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer. Clin Cancer Res 5 : 1231 1240.
57. Zhang ZW, Laurence NJ, Hollowood A, Newcomb P, Moorghen M, Gupta J et al (2004) Prognostic value of TP53 codon 72 polymorphism in advanced gastric adenocarcinoma. Clin Cancer Res 10 : 131 135.
58. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T et al (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27 : 110 117.
59. Zhou G, Zhai Y, Cui Y, Zhang X, Dong X, Yang H et al (2007) MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res 13 : 2627 2633.